Compare Kimberly Clark Corp (KMB) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Kimberly Clark Corp trades at $100.4 (market cap $33.06B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Kimberly Clark Corp is far larger — about 33.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Kimberly Clark Corp pays a 5.15% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 94 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KMB | MRVI | |
|---|---|---|
Market Cap | $33.06B | $977.37M |
Volume | 6,233,100 | 2,742,564 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $9.00 |
52-Week Low | $93.05 | $2.83 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $38.62B | $1.08B |
Dividend Yield | 5.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $98.29, down 0.49% on the day, showing bearish technical momentum with the stock near key support levels. The company maintains solid profitability with 11.79% net margins and has beaten earnings estimates in 2 of the last 3 quarters. Recent executive transitions and the pending Kenvue acquisition create both opportunities and uncertainties for the consumer staples giant.
KMB offers a compelling 5.2% dividend yield with 54 consecutive years of increases, though cash flow sustainability remains a concern. Analyst consensus targets $117.25 (19% upside) but the stock faces headwinds from integration risks and competitive pressures in the personal care market.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
